Business Of Biotech Gynecological Cancer Therapies with Context Therapeutics' Martin Lehr
Apr 18, 2022
Martin Lehr, Co-Founder & CEO of Context Therapeutics, discusses his transition from venture capitalist to startup CEO in the field of gynecological cancer therapies. Topics covered include their clinical trial approach, manufacturing process, and the challenges of transitioning from small molecules to bi-specific antibodies. The chapter also explores the benefits of investigator sponsored trials and collaborations with academic institutions.
Chapters
Transcript
Episode notes
1 2 3 4 5 6
Introduction
00:00 • 4min
Venture Capitalist to Startup CEO
04:00 • 20min
Transitioning from Small Molecules to Bi-Specific Antibodies
24:13 • 4min
Clinical Trial Approach and Manufacturing Process
27:50 • 8min
Investigator Sponsored Trials vs Outsourcing to CROs
36:09 • 9min
Honoring Women and Continuing the Conversation
45:15 • 2min